Empowering women and girls in HIV prevention

Partnership objective

Support the development and delivery of innovative tools to equip women and girls in developing countries with tools to protect themselves against sexual transmission of HIV.

The program supports the development and delivery of innovative tools to equip women and girls in developing countries with tools to protect themselves against sexual transmission of HIV. The program supports the development and delivery of innovative tools to equip women and girls in developing countries with tools to protect themselves against sexual transmission of HIV. Copyright Johnson & Johnson

What are the health needs and challenges?

HIV/AIDS remains among the greatest obstacles to women’s health and development. Although remarkable advances have been made in reducing new infections, progress has largely left women behind. In some parts of sub-Saharan Africa, young women and adolescent girls ages 15 to 24 are as much as eight times as likely to be infected as their male counterparts. Since stopping HIV’s spread among women requires a range of options to meet women’s individual needs, new tools including microbicides and multipurpose prevention technologies are being developed.

Description of partnership activities and how they address needs and challenges

The collaboration between Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and the International Partnership for Microbicides (IPM) supports the development and delivery of innovative tools to enable women and girls in developing countries to protect themselves against sexual transmission of HIV.

This is done by granting IPM royalty-free license in order to develop and commercialize its HIV medicine in a number of developing countries and use its HIV medicine darunavir as a potential vaginal and rectal microbicide for HIV prevention in women.

This represents the first time a pharmaceutical company has licensed a protease inhibitor to be developed as a microbicide. The license will ultimately ensure that any new product will be provided at low cost in the settings where it is most urgently needed.

Partnership information

Company(ies) Johnson & Johnson

Partner(s) International Partnership for Microbicides

Type of Partner(s) PDPs

Therapeutic Focus Infectious Diseases

Disease(s) HIV/AIDS

Program Type(s) Availability of Treatment - Technology Transfer - Manufacturing and Entrepreneurial Know-How, Availability of Treatment - Technology Transfer - Scientific Collaboration and Knowledge Sharing, Research & Development - Development of Treatments

Targeted Population(s) Women

Region(s) Sub-Saharan Africa

Number of Countries 48

Country(ies) Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sudan, Swaziland, Tanzania, The Gambia, Togo, Uganda, Zambia, Zimbabwe

Start Date 2016

More information Johnson & Johnson Press Release

Anticipated completion date Ongoing

« Our goal is to make HIV history. Much more remains to be done in the fight against HIV and that’s especially important in the world’s most vulnerable communities. »

Alex Gorsky, Chairman and CEO of Johnson & Johnson